Can Statins Help Older Adults Live Longer and Stay Independent? The PREVENTABLE Study

Principal Investigator: Elizabeth Jackson

Adults aged 75 and older represent one of the fastest‑growing segments of the U.S. population, yet they remain underrepresented in major prevention trials—especially those involving statins. Clinicians regularly debate whether statins provide meaningful benefits for healthy older adults without heart disease or dementia. PREVENTABLE directly addresses this gap. By studying outcomes that matter most to older adults—preserving memory, maintaining independence, and preventing disability—PREVENTABLE has the potential to reshape national guidelines and inform truly patient‑centered decisions about statin use in later life.

PREVENTABLE (NCT04262206) is a large, nationwide, Phase 4 randomized clinical trial led by Duke University. It is designed to determine whether the statin atorvastatin 40 mg can help community‑dwelling adults aged 75 and older live longer, stay independent, and maintain cognitive function—even if they have no prior history of cardiovascular disease or dementia.

The study plans to enroll 20,000 older adults from more than 100 U.S. sites, including both VA and non‑VA clinical centers. Participants are randomly assigned in a 1:1 ratio to receive either atorvastatin 40 mg daily or a placebo. They will be followed for up to five years (median 3.8 years).

PREVENTABLE is uniquely designed to maximize accessibility and participation:
• Study drug is mailed directly to participants every 90 days.
• Screening and enrollment can occur in person or via telehealth.
• Follow‑up is conducted centrally through a structured call‑center workflow.
• Annual assessments include telephone‑based cognitive testing and patient‑reported measures of physical function.
• Additional in‑person evaluations occur if automated screening flags concerns.

A major focus of PREVENTABLE is evaluating outcomes most relevant to healthy aging. The primary endpoints are whether participants:
• Develop new dementia, or
• Develop persistent disability, defined by decline in activities of daily living and functional abilities.

Secondary outcomes include death, mild cognitive impairment (MCI), cardiovascular events (such as heart attack, stroke, heart failure hospitalization, or revascularization), and other measures of cognitive and physical decline.

Because older adults often have complex health profiles, PREVENTABLE uses a detailed recruitment strategy—including electronic health record–based cohort identification—to ensure participants meet criteria and do not have contraindications to statin therapy.

PREVENTABLE is supported by the National Institute on Aging (NIA), the National Heart, Lung, and Blood Institute (NHLBI), and partners across academic and VA health systems. Results from this landmark study will provide definitive evidence about whether statin therapy should be recommended for primary prevention in adults over 75—helping clinicians and families make informed, individualized decisions about healthy aging.